Characterization of Dementia Due to Mixed Alzheimer and Subcortical Vascular Pathology The purpose of this study is to determine the clinical, cognitive, motor, brain imaging, genetic and biochemical biomarker characteristics of Alzheimer disease (AD), subcortical vascular disease (SVaD) and mixed dementia (AD + sVaD). Recruiting Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, DementiaArea Vancouver
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]). Recruiting Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's DiseaseArea VancouverAge 65-85
Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD)The purpose of this project is to conduct a proof of concept study in patients with probable Alzheimer's Disease who have mild to moderate hypertension, in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, Recruiting Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, High Blood PressureArea VancouverAge 55 and above
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD.Recruiting Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's DiseaseArea VancouverAge 50-85
MINT-01 (A Medium Chain Triglyceride INTervention for Alzheimer Disease (A MINT for AD Study) This study will test the safety and tolerability of a medium chain triglyceride (MCT) supplement in those with Alzheimer Disease (AD). recruitment poster Recruiting Principal Investigator Haakon NygaardBody Locations and Systems Alzheimer's DiseaseArea VancouverAge 50-90
Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND)The CCNA COMPASS-ND study aims to investigate the bases, commonalitites, and distinguishing characteristics of Alzheimer disease and related neurodegenerative disorders. recruitment poster Recruiting Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Dementia, Alzheimer's DiseaseArea VancouverAge 50-85
Microbiome in Alzheimer's DiseaseRecent evidence suggests a connection between the gut and the brain, and that certain conditions in the gut might be associated with neurological diseases. Research suggests that people with Alzheimer's Disease differ from healthy controls with respect to the bacteria (microbiome) present in theRecruiting Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's DiseaseArea VancouverAge 50-85
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at…The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of gantenerumab and solanezumab in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves cognitive outcomes and disease-relatClosed for Recruitment Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, Neurologic Diseases, DementiaArea VancouverAge 18-80
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseAZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2.Closed for Recruitment Principal Investigator Haakon NygaardBody Locations and Systems Alzheimer's DiseaseArea VancouverAge 55-85
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237. Closed for Recruitment Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, DementiaArea Vancouver
